Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C-C chemokine receptor 9 (CCR9) and anti-α4β7 integrin blocking antibodies
Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-α4β7 integrin antibody such as vedolizumab. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-α4β7 integrin antibody.
1. A method of treating or reducing the development of inflammatory bowel disease in a mammal, said method comprising administering to said mammal a suitable amount of a CCR9 chemokine receptor inhibitor in combination with an anti-α4β7 integrin blocking antibody,
wherein the CCR9 chemokine receptor inhibitor is
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the inflammatory bowel disease is Crohn's disease (CD) or ulcerative colitis (UC).
3. The method of claim 1 , wherein the anti-α4β7 integrin blocking antibody is vedolizumab (ENYVIO®).
4. The method of claim 1 , wherein the CCR9 chemokine receptor inhibitor and the anti-α4β7 integrin blocking antibody are administered in a combination formulation.
5. The method of claim 1 , wherein the CCR9 chemokine receptor inhibitor and the anti-α4β7 integrin blocking antibody are administered sequentially.
6. The method of claim 5 , wherein the CCR9 chemokine receptor inhibitor is administered prior to the anti-α4β7 integrin blocking antibody.
7. The method of claim 5 , wherein the CCR9 chemokine receptor inhibitor is administered after administration of the anti-α4β7 integrin blocking antibody.